Beam Therapeutics Inc. BEAM
We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities.
Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA. This approach uses a chemical reaction designed to create precise, predictable and efficient genetic outcomes at the targeted sequence. Our proprietary base editors have two principal components: (i) a clustered regularly interspaced short palindromic repeats, or CRISPR, protein, bound to a guide RNA, that leverages the established DNA-targeting ability of CRISPR, but is modified to not cause a double-stranded break, and (ii) a base editing enzyme, such as a deaminase, which carries out the desired chemical modification of the target DNA base. We believe this design contributes to a more precise and efficient edit compared to traditional gene editing methods, with the potential to dramatically increase the impact of gene editing. We are also pursuing a suite of delivery modalities, including both ex vivo and in vivo approaches, depending on tissue type. The elegance of the base editing approach, combined with a tissue specific delivery modality, provides the basis for a targeted, efficient, precise, and highly versatile gene editing system that is designed to be capable of gene correction, gene silencing, gene activation, gene modification, and/or multiplex editing of several genes simultaneously.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $139.7M | $63.5M | $377.7M | $60.9M | $51.8M | $24.0K | $18.0K | — |
| R&D | $409.6M | $367.6M | $437.4M | $311.6M | $387.1M | $103.2M | $54.6M | — |
| SG&A | $113.8M | $111.5M | $116.8M | $87.8M | $57.2M | $29.6M | $20.6M | — |
| Total operating expenses | $523.4M | $479.1M | $554.2M | $399.4M | $444.3M | $132.8M | $75.2M | — |
| Operating income | -$383.7M | -$415.6M | -$176.5M | -$338.5M | -$392.5M | -$132.8M | -$75.2M | — |
| Pre-tax income | -$80.0M | -$376.7M | -$131.2M | -$260.2M | -$370.6M | -$194.6M | -$78.3M | — |
| Income tax | $0 | $39.0K | $1.4M | $3.4M | $0 | $0 | $0 | — |
| Net income | -$80.0M | -$376.7M | -$132.5M | -$289.1M | -$370.7M | -$194.6M | -$78.3M | — |
| EPS, basic | -0.81 | -4.58 | -1.72 | -4.13 | -5.77 | -4.19 | -14.05 | — |
| EPS, diluted | -0.81 | -4.58 | -1.72 | -4.13 | -5.77 | -4.19 | -14.05 | — |
| Shares, diluted (wtd. avg.) | 98.9M | 82.3M | 77.2M | 70.0M | 64.2M | 46.7M | 6.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $294.9M | $282.0M | $435.9M | $245.5M | $572.7M | $177.0M | $50.6M | $147.9M |
| Short-term investments | $950.3M | $568.8M | — | — | — | — | — | — |
| Total current assets | $1.27B | $878.1M | $1.21B | $1.09B | $1.27B | $308.3M | $94.5M | — |
| Property, plant and equipment | $104.5M | $111.4M | $125.0M | $115.6M | $84.3M | $38.5M | $24.3M | — |
| Total assets | $1.48B | $1.10B | $1.46B | $1.34B | $1.47B | $451.7M | $156.1M | — |
| Accounts payable | $10.2M | $3.9M | $1.6M | $9.0M | $7.5M | $6.3M | $7.8M | — |
| Total current liabilities | $96.9M | $182.1M | $205.6M | $223.6M | $213.4M | $102.3M | $29.1M | — |
| Total liabilities | $242.8M | $370.3M | $478.4M | $608.2M | $647.7M | $206.1M | $55.2M | — |
| Retained earnings | -$1.64B | -$1.57B | -$1.19B | -$1.06B | -$768.3M | -$397.6M | -$203.0M | — |
| Total equity | $1.24B | $733.5M | $981.3M | $733.5M | $826.7M | $245.6M | -$201.1M | -$117.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$345.1M | -$347.2M | -$149.2M | $22.5M | -$66.3M | -$95.7M | -$72.0M | — |
| Depreciation and amortisation | $22.3M | $21.9M | $20.0M | $14.1M | $7.5M | $4.7M | $3.5M | — |
| Stock-based compensation | $94.2M | $120.7M | $98.6M | $84.3M | $43.6M | $15.4M | $7.0M | — |
| Capital expenditure | $14.9M | $8.9M | $33.7M | $49.0M | $46.8M | $16.4M | $12.5M | — |
| Investing cash flow | -$121.4M | $185.0M | $71.8M | -$461.3M | -$294.1M | -$100.1M | -$66.7M | — |
| Financing cash flow | $478.0M | $7.7M | $276.4M | $111.6M | $756.1M | $322.3M | $41.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-161512.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $18.0K | $24.0K | $51.8M | $60.9M | $377.7M | $63.5M | $139.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$78.3M | -$194.6M | -$370.7M | -$289.1M | -$132.5M | -$376.7M | -$80.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Material agreement signed Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |